<SEC-DOCUMENT>0001104659-25-099916.txt : 20251016
<SEC-HEADER>0001104659-25-099916.hdr.sgml : 20251016
<ACCEPTANCE-DATETIME>20251016082357
ACCESSION NUMBER:		0001104659-25-099916
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20251016
DATE AS OF CHANGE:		20251016

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Theriva Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-282024
		FILM NUMBER:		251396435

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Synthetic Biologics, Inc.
		DATE OF NAME CHANGE:	20120305

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>tm2528885d2_424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B><BR>
Filed pursuant to Rule 424(b)(5)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Registration
No. 333-282024</B></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>PROSPECTUS SUPPLEMENT NO. 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">(to the prospectus dated September 25, 2024)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><IMG SRC="tm2528885d2_424b5img01.jpg" ALT="Theriva??? Biologics Announces U.S. FDA ..." STYLE="height: 114px; width: 341px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Theriva Biologics,
Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>1,385,000 Shares of
Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus supplement updates, amends and
supplements the prospectus contained in our Registration Statement on Form S-1, as amended, effective as of September 25, 2024 (as supplemented
or amended from time to time, the &ldquo;Prospectus&rdquo;) (Registration No. 333-282024) relating to the offer and sale of up to 918,600
shares of common stock, par value $0.001 per share (the &ldquo;Common Stock&rdquo;), of Theriva Biologics, Inc. (the &ldquo;Company&rdquo;),
1,428,600 shares of Common Stock issuable upon the exercise of 1,428,600 common warrants to purchase shares of Common Stock (the &ldquo;Existing
Warrants&rdquo;), 510,000 pre-funded warrants to purchase up to 510,000 shares of common stock, and 1,938,600 shares of Common Stock underlying
the Existing Warrants and pre-funded warrants purchased by investors in a best efforts public offering that was consummated on or about
September 27, 2024. This Prospectus Supplement No. 1 (the &ldquo;Prospectus Supplement&rdquo;) is being filed in connection with an amendment
to certain of the Existing Warrants as described below under &ldquo;Amendments to Existing Warrants.&rdquo; Capitalized terms used in
this Prospectus Supplement and not otherwise defined herein have the meanings specified in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This Prospectus Supplement
is not complete without the Prospectus. This Prospectus Supplement should be read in conjunction with the Prospectus, which is to be delivered
with this Prospectus Supplement, and is qualified by reference thereto, except to the extent that the information in this Prospectus Supplement
updates or supersedes the information contained in the Prospectus. Please keep this Prospectus Supplement with your Prospectus for future
reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our shares of Common
Stock are listed on the NYSE Capital Market under the symbol &ldquo;TOVX&rdquo;. On October 15, 2025, the closing price for our shares
of Common Stock on the NYSE Capital Market was $0.84 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Investing in our securities
involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks and uncertainties
under the heading &ldquo;Risk Factors&rdquo; beginning on page 6 of the Prospectus.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B>Neither the SEC nor
any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus
or this Prospectus Supplement. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>AMENDMENTS TO EXISTING
WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This Prospectus Supplement
is being filed to disclose the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On October 16, 2025,
we entered into an amendment with certain holders of Existing Warrants to purchase up to 1,385,000 shares of Common Stock held in the
aggregate by such holders in order to amend the exercise price under such Existing Warrants from $2.00 to $0.54 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>The date of this Prospectus
Supplement is October 16, 2025.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B></B></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2528885d2_424b5img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2528885d2_424b5img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !R 54# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYKEP0H4'YCN_BR,_7-?2-=6+H0H22C+FN84:CJ)MJPM%%%<IN%%%% !1110
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M#EZ'EWPC_P"2BV7_ %QF_P#0#7T<.M?./PC_ .2BV7_7&;_T U]'#K79F_\
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MBC&%7Y2>!]37)B:V&FE"C&UGOW-:4*JO*;/&-&^*/BR]UO3K:XO86BGN8XW
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M5"J  !@ =J=117S!](-[5P/QB_Y)_/\ ]?$7_H5=]VK@?C#_ ,D_G_Z^(O\
MT*NK!_[Q#U1C6_AR]#R[X1_\E%LO^N,W_H!KZ.']*^<?A)_R4:R_ZY3?^@&O
MHX?TKLS?^.O1?J8X/^'\QW:ODWQ5_P C9K7_ %^S?^A&OK+M7R;XJ_Y&S6O^
MOV;_ -"-;9-_$EZ$8WX4?3?A<!?"ND@  "SBX'^Z*UZR?#'_ "*VE?\ 7I%_
MZ"*UJ\67Q,[8[(^;?BO_ ,E$OO\ KG%_Z#7<Z.C/^S]<JH)/V28X'H&)-<+\
M5S_Q<2^_ZYQ?^@UZS\,88[GX8V,$RAHY4D1U/<%B#7OXI\N$I2[6_(X*:O6F
MO4^?=,L[F_U.VL[-@MS/((XB7V?,>G/:NU_X5=X[]$_\#JYWQ5X<O?"/B&2S
MDWJBOYEI..-Z9X(/J.]>D^&_C1:BT2#Q#;S+.@P;F!=RR>Y7L:Z\55KN*J8=
M*29A2A"[C4T9S'_"K?'?^S_X'5"_PC\9/N+6ULS'J3= DUZ)?_&CPW!;EK..
MZNYL?*@CV#\2>E4? GQ1N=?U^73-6A2-KEBUH85.$Q_ WX<[JXUB<<H.;@DE
MY&WL\.Y*-S<\:6TMG\'KVVGP)H;&-'P<C(*@UXY\.5#?$+1P1D"1C^.TU[E\
M3/\ DG.M_P#7$?\ H2UXA\-?^2AZ1_UT;_T TL [X2J_7\BL0OWL$?3?>LWQ
M!_R+FJ?]>DO_ * :TN]9OB#_ )%S5/\ KTE_] ->#'='>]CY;\-_\C-H_P#U
M^0_^ABOK8=*^2?#?_(S:/_U^0_\ H8KZV'2O;SGXX>AP8+X6?.7Q7T#^Q_&$
MEU%'MM=17SEP. _1Q^?/XUZ-\+/%$5WX&DCO)<2:2"DA)Y\H#*G\LC\*T/BA
MX>.N^#[AH4W75D?M$6.I ^\/Q&?R%?/=EJMW86M[!:S%(KZ$0SC^\N<_Y^IK
M:E%8W!J#WB_Z_ B;="LY=&7=2O+OQ?XMFG0%KC4+D+$O7:I.%'X#%?3NB:9#
MHNB6>F0#]W;1",'U(ZG\3DUXO\&?#_V[7KC69DS#9+LBR.#*P_H/YBO>:X\T
MJKF5&.T3;"PT<WNSPSXB?$K43K%SH^B7)MK:V8QR7$9^=W'W@#V /'%<_I_@
MCQIXDMUOU\\Q2C<DMU=%2X]0"<XK!\4V5QI_BC5;6Y4K*MRYY[@G(/T(->Y>
M'/B7X9O='MDN;^.QN(HE22&8%<$#'!Z$5WU.;#4(O#QO?=VN<\;5:C]H['F%
MY\,/%UE93W5P8?)AC:23%V3\H&3Q7-^&/F\6:*?^GZ'_ -#%>K>._BGI;Z/<
M:7H<OVN>Y0Q/.%(2-3P<9ZG%>4^%^/%NB_\ 7]#_ .ABM\/4K5*$I5E;M]QE
M5C",TH.Y]9T445\F>T%%%% !1110 4A&1@]Z6B@#SS7/A^2SW&DR9))8V\A_
M]!/^-<+/;W%G<&.>.2"9#]UA@BO>ZSM3T>PUB QWD"28^ZPX9?H:]K"9O4I^
M[5]Y?C_P3YW&Y)3J^_0]U_A_P#S6S\<:O:636Q=)FZ)+*,LH_K^-8-U=W%].
MTUW,\LC=68Y_+TKK;OX>7:WJK9W$;V['EGX9![CO75:+X1T[1PLFS[1<@?ZZ
M4?R':N]XW!4%[2DKM]OZT/,CE^/Q+]E6;48]_P!.YP^B>"]1U3;)/FTMSSN=
M?F8>P_QKTC1]'M-&LOLMJ&VYRS,<ECZFM(=.U%>'BL=6Q.DG9=CZ/!Y=0PNL
M%>7<=1117$>D)7/>,?#0\5>'WTO[2;?=(C^8$W?=.<8KH:*<).$E*.Z$TFK,
M\W\)?"I?"WB&'5AJSW)B1U\LPA<[ACKFO2*3\:7M6E6M.M+FJ.[)A",%:(F,
MCFO*-5^"R:GJU[??VV\?VF9Y=GD [=QSC.:]7_&EIT<14HMNF[!.G&?Q(IZ7
M9?V=I=I9[_,^SPK%OQC.T8S5VBBL6VW=EGFGBKX4KXG\13ZL=6>W\Y54QB$-
MC:,=<UU_A30!X9\.VVE"X,X@W?O"NW.23T_&MH>E1RR"&)Y&SM4%CCT%;3KU
M9P5.3T1DJ<(MR11UG0=-\0V)L]3M4N(3R-PY4^JGJ#7FNH? VU:1FT[69H4/
M2.>,/C\1BNVC\;64L(F2RU!HB,[Q!D8_.MRQO[?4K2.ZM7\R)QD'%;0J8G"K
M2Z1A&IA\0[1:;/);;X%OO_TO7OD](8.?U->@^&?!6B^%(F_L^W)N'&'N)3ND
M;VSV'L*U+#5;?4;B[AA5PUJ_EON& 3[5'JVN6.CHGVEV,DAQ''&-SO\ 045<
M1B:S]G)M^0X^PIQ]HK)=R/Q-HW_"0^';W2?.,/VI GF!=VWD'I^%<3X;^$B^
M'_$-GJPUEYS;,6\LP@;L@CKGWKK;+Q797=TEK-%<VDTG^K6XCV;_ *5L7ETE
ME9S7+@E(D+L%'. ,U,:F(HITEHI?CT'&=&LO:)WM^!9'-5-1M1?:==6F_9Y\
M31[L9V[@1G]:6PO4U"RANHPPCE0.H8<X/K4LLT<$32RNJHHRS,< "N:S3MU-
MU*,H\W0\JT[X*II^IV=Y_;CO]FF27;Y &[:0<=?:O6>GIBN8/C:PR62UO9+=
M3@W"0$I]<^E;]I>P7]LEQ:RK)$XRK#O73B)5YVE6.>A5H2;C2:)F0.I5@"I&
M"#WKR6[^!UO->3RP:U)##)(S)%Y .P$YQG/:O2-6UVST9$%PS-+)]R*)=SO]
M!52R\665W<I;31W-G/)_JTN8]F_Z&G0EB*47.E>S"I5P[G[.;5Q?"7ANW\*>
M'XM+@D,I5F>24C!D8GDX_3\*WN,5#<3I;VTD[_<C0N<=< 9J+3K^+4K"*\A#
M".5=R[A@XKFDYSO-_P!,Z$XQ:@MS"\5^ ]'\7*LEW&\-XB[4N83AP/0]F'L:
M\^F^!5QYG[K7D,?^W;\_H:],U'Q58V%T;14GNKE1EHK>/>5^M3Z3X@L]8,D<
M!>.>+[\,R[77\*[:=?%4:?NWY3EE+#5*G(VN8X[P]\(-'TAS<7<\E]=;2(VD
M4!(R1C(7N?K6=IGP633=6L[W^W'E-O.DVPP ;MK XZ^U>CZIK-IH]NLMR['<
MVU$1<LY] *I6/BJSN[I+66"ZM)I/]6MS%LW_ $H6)Q<HN:;:82>'C)4VU<Z"
MBBBN [0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
IHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
